Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 2/20 | 0.48 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.45 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.43 |
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.48 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.48 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11353187 | 0.98 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1KMT2APARP10PARP4 | |
| Terephthalamide SCHEMBL1087289 | 0.82 | PARP1 (0.67) | ALDH1A1L3MBTL1KMT2APARP10PARP4 | |
| Terephthalamide SCHEMBL11512422 | 0.82 | PARP1 (0.67) | ALDH1A1L3MBTL1KMT2APARP10PARP4 | |
| Hydrochloric Acid SCHEMBL83661 | 0.81 | TSHR (0.57) | ALDH1A1KMT2AMAPTTSHRPOLB | |
| SCHEMBL4853473 | 0.80 | MAPK13 (0.52) | ALDH1A1L3MBTL1KMT2AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL28169553 | 0.79 | MPO (0.61) | ALDH1A1L3MBTL1KMT2AMAPTPOLB | |
| Hydrazine SCHEMBL28169554 | 0.79 | TSHR (0.55) | ALDH1A1KMT2AMAPTTSHRPOLB | |
| Terephthalamide SCHEMBL23774 | 0.79 | PARP1 (0.71) | ALDH1A1L3MBTL1KMT2APARP10PARP4 | |
| SCHEMBL24206451 | 0.78 | MAPT (0.44) | ALDH1A1L3MBTL1KMT2AMAPTPOLB | |
| SCHEMBL7034 | 0.78 | TSHR (0.60) | ALDH1A1KMT2AMAPTTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118511876-A | Tebufenozide nano-suspension agent and preparation method thereof | 山西奇星农药有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118511876-A | Tebufenozide nano-suspension agent and preparation method thereof | 山西奇星农药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-8741944-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-03 | — | — | US | disclosed |
| US-8580827-B2 | Anti-Francisella agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-11-12 | — | — | US | disclosed |
| US-8546441-B2 | PDK-1/AKT signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-8541460-B2 | Phosphoinositide-dependent kinase-1 (PDK-1) inhibitors; for the treatment and prevention of cancer in humans; 4-[5-(2-Phenanthracenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenecarboxamide | THE OHIO STATE UNIVERSITY (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2246332-B1 | Pyrazole derivatives as anti-francisella agents | UNIV OHIO STATE RES FOUND (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-8445483-B1 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-02 | — | — | US | disclosed |
| EP-1696907-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060142368-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MRDC | 2006-06-29 | — | — | US | disclosed |
| US-20060079566-A1 | PDK-1/Akt signaling inhibitors | THE NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-04-13 | — | — | US | disclosed |
| US-7026346-B2 | Compounds and methods for inducing apoptosis in proliferating cells | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1499597-A4 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS | UNIV OHIO STATE RES FOUND (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005044130-A9 | PDK-1/AKT SIGNALING INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005044130-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-1499597-A2 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20030236294-A1 | Compounds and methods for inducing apoptosis in proliferating cells | NIH - DEITR | 2003-12-25 | — | — | US | disclosed |
| WO-2003086287-A2 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079566-A1 | PDK-1/Akt signaling inhibitors | PDPK1, PDXK, PDK3 | PARP1 681/4885CA2 2951/4885ROCK1 449/4885 |
| US-20030236294-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MCL1, BRDT, BAD | PARP1 1201/4885CA2 637/4885ROCK1 326/4885 |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | PARP1 2906/4885CA2 2425/4885ROCK1 1300/4885 |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | PARP1 2906/4885CA2 2425/4885ROCK1 1300/4885 |
| US-20060142368-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MCL1, BRDT, BAD | PARP1 990/4885CA2 659/4885ROCK1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.